Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Pharmacoepidemiology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1517546
This article is part of the Research Topic Advances in Drug-induced Diseases Volume II View all 37 articles

Overweight and glucose/lipid metabolism abnormality associated with SSRIs: a pharmacovigilance study based on the FDA Adverse Event Reporting System

Provisionally accepted
Jinming Cao Jinming Cao 1,2Zhicong Chen Zhicong Chen 1Yan Wang Yan Wang 2Yunpeng Ma Yunpeng Ma 2Zhen Yang Zhen Yang 2Jian Cai Jian Cai 3Zhijun Xiao Zhijun Xiao 2Feng Xu Feng Xu 2*
  • 1 School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
  • 2 Fengxian District Central Hospital, Shanghai, Shanghai Municipality, China
  • 3 Fengxian Mental Health Center, shanghai, China

The final, formatted version of the article will be published soon.

    In the past few decades, selective serotonin reuptake inhibitors (SSRIs) became widely used antidepressants worldwide. Therefore, the adverse reactions of patients after SSRI administration became a public and clinical concern. In this study, we conducted a pharmacovigilance study using the Adverse Event Reporting System (FAERS) database of the US Food and Drug Administration. Our main goal was to evaluate adverse events related to SSRIs, with a particular focus on abnormal weight gain and glucose/lipid metabolism disorders.The adverse event data for representative SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline) was extracted from the FAERS database from 2004Q1 to 2023Q4.The reporting odds ratio and proportional reporting ratio were employed to explore relevant adverse event reports (ADEs) signals. Univariate logistic regression analysis was utilized to explore factors associated with glucose/lipid metabolism abnormality following SSRIs treatment. 2 Results: We identified 143,744 ADE reports associated with SSRIs and revealed significant abnormal signals related to weight gain and glucose/lipid metabolism in depressed patients. Variations were observed among different SSRIs medications. Specifically, citalopram was associated with abnormal

    Keywords: Selective Serotonin Reuptake Inhibitors, FAERS, Overweight, ADEs, glucose/lipid metabolism disorders

    Received: 26 Oct 2024; Accepted: 31 Dec 2024.

    Copyright: © 2024 Cao, Chen, Wang, Ma, Yang, Cai, Xiao and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Feng Xu, Fengxian District Central Hospital, Shanghai, 201400, Shanghai Municipality, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.